AstraZeneca’s Tagrisso (osimertinib) Receives EU’s CHMP Positive Opinion for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

 AstraZeneca’s Tagrisso (osimertinib) Receives EU’s CHMP Positive Opinion for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

AstraZeneca Reports Updated Results of Imfinzi in P-III Studies for NSCLC and ES-SCLC

Shots:

  • The recommendation is based P-III ADAURA trial assessing Tagrisso (80mg, qd, PO) vs PBO in 682 patients with stage IB, II, IIIA EGFRm NSCLC following complete tumor resection and adjuvant CT as indicated for 3 yrs. or until disease recurrence
  • The study showed improvement in DFS in all primary analysis population of patients with Stage II and IIIA EGFRm NSCLC and in the overall trial population of patients with Stage IB-IIIA disease, 80% reduction in the risk of disease recurrence or death
  • Tagrisso is approved to treat early-stage lung cancer in more than 15 countries, including US and China, and additional global regulatory reviews are ongoing

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Al Jazeera

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post